论文部分内容阅读
目的分析33 945例宫颈病变的筛查结果,并探讨DNA倍体定量分析技术在宫颈病变筛查中的应用价值。方法纳入2012年至2015年该院行宫颈病变筛查的妇女33 945例,年龄18~74岁,取宫颈细胞标本,同时进行常规细胞学检查诊断及DNA倍体定量分析,筛查结果阳性者再进一步行阴道镜下宫颈活检组织病理学诊断。结果 2012~2015年宫颈病变筛查阳性率呈降低趋势(P<0.05)。DNA倍体分析系统筛查宫颈病变的阳性率为9.28%,高于常规细胞学的6.82%(P<0.05)。DNA倍体分析的活检阳性率为30.52%,高于常规细胞学的18.22%(P<0.05);DNA定量分析的宫颈癌阳性检出率为0.144%,也高于常规细胞学的0.076%(P<0.05)。结论该院就诊妇女宫颈病变检出率有逐年下降趋势。DNA定量分析法可提高宫颈癌及癌前病变的早期筛查率及活检阳性率。
Objective To analyze the screening results of 33 945 cases of cervical lesions and to explore the value of DNA ploidy quantitative analysis in the screening of cervical lesions. Methods A total of 33 945 women aged 18-74 years who underwent cervical screening in the hospital from 2012 to 2015 were enrolled in this study. Cervical cells were collected for cervical cytology and routine cytological examination and DNA ploidy quantitative analysis. The results of screening were positive Further line colposcopic cervical biopsy histopathological diagnosis. Results The positive rate of cervical lesions from 2012 to 2015 showed a decreasing trend (P <0.05). The positive rate of DNA ploidy system in screening cervical lesions was 9.28%, which was 6.82% higher than that of routine cytology (P <0.05). The positive rate of DNA ploidy analysis was 30.52%, higher than that of routine cytology 18.22% (P <0.05). The positive rate of cervical cancer by DNA quantitative analysis was 0.144%, which was also higher than that of conventional cytology (0.076% P <0.05). Conclusions The detection rate of cervical lesions in women visiting this hospital has been declining year by year. DNA quantitative analysis can improve the early screening rate of cervical cancer and precancerous lesions and the positive rate of biopsy.